Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.
Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.
复制标题
奈非那韦在人类免疫缺陷病毒感染婴儿中的药代动力学。
DOI：
10.1097/00006454-200108000-00006
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
PediatricACTG356Investigators
中科院分区：
文献类型：
--
作者：
Capparelli,EV;Sullivan,JL;Mofenson,L;Smith,E;Graham,B;Britto,P;Becker,MI;Holland,D;Connor,JD;Luzuriaga,K;PediatricACTG356Investigators
Background.Nelfinavir dosed at∼ 20 to 30 mg/kg three times a day (TID) in older children provides exposure similar to 750 mg TID in adults. However, the pharmacokinetics (PK) of nelfinavir in infants who are< 2 years of age is not well-described. The objective of this study was to determine the pharmacokinetics of nelfinavir in infants< 2 years of age.Methods.Nelfinavir concentrations were evaluated in 22 HIV-infected infants between 15 days and 2 years of age receiving nelfinavir as part of Pediatric ACTG Study 356. Nelfinavir therapy was initiated at∼ 25 mg/kg TID (n= 18) or∼ 55 mg/kg twice a day (n= 4) and given in combination with nevirapine, stavudine and lamivudine. PK samples were obtained predose and 1.5 and 4 h postdose at∼ 6-month intervals. Eight infants (all≤ 3 months of age) also had intensive PK samples collected at Week 1.Results.The median apparent clearance in the infants with intensive pharmacokinetic sampling was 2.7 liters/h/kg (range, 1.8 to≥ 10) and was similar between twice a day and TID dosing cohorts. Overall nelfinavir concentrations at all collection times were lower in these infants than previously reported in older pediatric patients.Conclusions.Nelfinavir concentrations in infants are highly variable and lower than those seen in adult or older pediatric populations receiving labeled dosing. Therefore it is necessary to further evaluate nelfinavir safety, effectiveness and pharmacokinetics at higher doses than used among other pediatric populations.
登录
查看更多内容
影响因子：
158.5
作者：
Gulick, RM;Mellors, JW;Chodakewitz, JA
通讯作者：
Chodakewitz, JA
青少年的药代动力学变异性：身体大小和器官功能对剂量方案设计的影响。
DOI：
10.1016/s1054-139x(94)90633-5
发表时间：
1994
期刊：
The Journal of adolescent health : official publication of the Society for Adolescent Medicine
影响因子：
--
作者：
Rodman,JH
通讯作者：
Rodman,JH
利托那韦加沙奎那韦治疗的晚期 HIV 感染患者的毒性、疗效、血浆药物浓度和蛋白酶突变
DOI：
--
发表时间：
1997
期刊：
AIDS (London)
影响因子：
--
作者：
Patrizio Lorenzi;S. Yerly;Karmine Abderrakim;M. Fathi;O. Rutschmann;J. von Overbeck;D. Leduc;L. Perrin;B. Hirschel
通讯作者：
B. Hirschel
影响因子：
6.4
作者：
Markowitz, M;Conant, M;Ho, DD
通讯作者：
Ho, DD
茚地那韦的低血浆浓度与 HIV-1 感染者接受含茚地那韦三联疗法的病毒学治疗失败有关
影响因子：
1.2
作者：
D. Burger;R. Hoetelmans;P. Hugen;J. Mulder;P. Meenhorst;P. Koopmans;K. Brinkman;M. Keuter;W. Dolmans;Y. Hekster
通讯作者：
Y. Hekster